MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-21-2025
Intra-Cellular Therapies EBITDA 2011-2026 | ITCI
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Intra-Cellular Therapies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -116 M | -159 M | -263 M | -285 M | -231 M | -154 M | -162 M | -103 M | -118 M | -106 M | -31 M | - | -16.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -16.4 M | -285 M | -145 M |
Quarterly EBITDA Intra-Cellular Therapies
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -20.8 M | - | - | - | -48.3 M | - | -55.1 M | -87.6 M | -72.5 M | - | -76.9 M | -68.9 M | -53.1 M | - | -55.8 M | -64.7 M | -48.9 M | - | -36.2 M | -39.1 M | -36.6 M | - | -43.1 M | -39 M | -37 M | - | -23.6 M | -18.5 M | -27.7 M | - | -30 M | -31.4 M | -28.4 M | - | -32.3 M | -21.6 M | -22.4 M | - | -6.5 M | -4.61 M | -4.57 M | - | -4.78 M | -8.04 M | -5.39 M | - | -2.18 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.18 M | -87.6 M | -35 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | USA |
 |
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amgen
AMGN
|
14.2 B | $ 345.82 | 1.71 % | $ 186 B | USA |
 |
Amneal Pharmaceuticals
AMRX
|
451 M | $ 12.61 | 2.35 % | $ 3.95 B | USA |
 |
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
argenx SE
ARGX
|
-349 M | $ 776.24 | 1.41 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 24.35 | 4.64 % | $ 3.1 B | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.44 | 5.51 % | $ 383 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.85 | 2.39 % | $ 9.26 B |  Australia |
 |
CymaBay Therapeutics
CBAY
|
-101 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
-2.45 M | $ 2.74 | 6.42 % | $ 17.2 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 91.34 | 1.92 % | $ 27.2 B | Germany |
 |
Avid Bioservices
CDMO
|
-7.57 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 4.63 | 1.87 % | $ 767 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
-171 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 3.07 | 1.32 % | $ 6.68 B | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-76 M | - | - | $ 401 M | USA |
 |
Cerus Corporation
CERS
|
-7.26 M | $ 1.94 | 5.43 % | $ 370 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-77.8 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-8.42 M | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
-22.8 M | $ 2.92 | 6.18 % | $ 7.62 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-209 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
505 K | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Coherus BioSciences
CHRS
|
-180 M | $ 1.68 | 0.6 % | $ 197 M | USA |